Cinanserin
Quipazine
Methysergide
An ergot derivative that is a congener of LYSERGIC ACID DIETHYLAMIDE. It antagonizes the effects of serotonin in blood vessels and gastrointestinal smooth muscle, but has few of the properties of other ergot alkaloids. Methysergide is used prophylactically in migraine and other vascular headaches and to antagonize serotonin in the carcinoid syndrome.
Serotonin Antagonists
Receptors, Serotonin
Serotonin
A biochemical messenger and regulator, synthesized from the essential amino acid L-TRYPTOPHAN. In humans it is found primarily in the central nervous system, gastrointestinal tract, and blood platelets. Serotonin mediates several important physiological functions including neurotransmission, gastrointestinal motility, hemostasis, and cardiovascular integrity. Multiple receptor families (RECEPTORS, SEROTONIN) explain the broad physiological actions and distribution of this biochemical mediator.
Lysergic Acid Diethylamide
Semisynthetic derivative of ergot (Claviceps purpurea). It has complex effects on serotonergic systems including antagonism at some peripheral serotonin receptors, both agonist and antagonist actions at central nervous system serotonin receptors, and possibly effects on serotonin turnover. It is a potent hallucinogen, but the mechanisms of that effect are not well understood.
Hallucinogens
Drugs capable of inducing illusions, hallucinations, delusions, paranoid ideations, and other alterations of mood and thinking. Despite the name, the feature that distinguishes these agents from other classes of drugs is their capacity to induce states of altered perception, thought, and feeling that are not experienced otherwise.
Psilocybine
Mescaline
Hallucinogenic alkaloid isolated from the flowering heads (peyote) of Lophophora (formerly Anhalonium) williamsii, a Mexican cactus used in Indian religious rites and as an experimental psychotomimetic. Among its cellular effects are agonist actions at some types of serotonin receptors. It has no accepted therapeutic uses although it is legal for religious use by members of the Native American Church.
Receptor, Serotonin, 5-HT2A
A serotonin receptor subtype found widely distributed in peripheral tissues where it mediates the contractile responses of variety of tissues that contain SMOOTH MUSCLE. Selective 5-HT2A receptor antagonists include KETANSERIN. The 5-HT2A subtype is also located in BASAL GANGLIA and CEREBRAL CORTEX of the BRAIN where it mediates the effects of HALLUCINOGENS such as LSD.
2,5-Dimethoxy-4-Methylamphetamine
Aplysia
Ganglia
Electrophysiology
Waxes
A plastic substance deposited by insects or obtained from plants. Waxes are esters of various fatty acids with higher, usually monohydric alcohols. The wax of pharmacy is principally yellow wax (beeswax), the material of which honeycomb is made. It consists chiefly of cerotic acid and myricin and is used in making ointments, cerates, etc. (Dorland, 27th ed)
Magnesium
Ganglia, Invertebrate
Clusters of neuronal cell bodies in invertebrates. Invertebrate ganglia may also contain neuronal processes and non-neuronal supporting cells. Many invertebrate ganglia are favorable subjects for research because they have small numbers of functional neuronal types which can be identified from one animal to another.
Nephropidae
Brachyura
Pylorus
Interneurons
Neurons
Periodicity
Taraxacum
Urtica dioica
Caesalpinia
A plant genus of the family FABACEAE. The common name of "Bird-Of-Paradise" is also used for other plants such as Heliconia (HELICONIACEAE) and Strelitzia (STRELITZIACEAE) and some birds. The common name of "Cat's-Claw" is more often used with UNCARIA. The common name of "Pernambuco" also refers to a state in Brazil. Furanoditerpenoid lactones and caesalpin are produced by members of this genus.
Dengue Virus
Ginger
Dengue
Inhibitory Concentration 50
Adenylate Cyclase
Methoxydimethyltryptamines
Compounds that contain the biogenic monoamine tryptamine and are substituted with one methoxy group and two methyl groups. Members of this group include several potent serotonergic hallucinogens found in several unrelated plants, skins of certain toads, and in mammalian brains. They are possibly involved in the etiology of schizophrenia.
Dopamine
One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action.
Bufotenin
Adenylate Cyclase Toxin
Cyproheptadine
Tablets
Therapeutic Equivalency
Love
Academic Medical Centers
Evidence for a role for central 5-HT2B as well as 5-HT2A receptors in cardiovascular regulation in anaesthetized rats. (1/28)
1. The effects of injections i.c.v. of quipazine, (2 micromol kg-1) and 1-(2,5-di-methoxy-4-iodophenyl)-2-aminopropane (DOI; 2 micromol kg-1) on renal sympathetic and phrenic nerve activity, mean arterial blood pressure (MAP) and heart rate were investigated in alpha-chloralose anaesthetized rats pretreated with a peripherally acting 5-HT2 receptor antagonist. 2. Quipazine or DOI caused a rise in MAP which was associated with a tachycardia and renal sympathoinhibition in rats pretreated (i.c.v.) with the antagonist vehicle 10% PEG. These effects of quipazine were completely blocked by pretreatment with cinanserin (a 5-HT2 receptor antagonist) and attenuated by spiperone (a 5-HT2A receptor antagonist). However, pretreatment with SB200646A (a 5-HT2B/2C receptor antagonist) only blocked the sympathoinhibition, while pretreatment with SB204741 (a 5-HT2B receptor antagonist) reversed the sympathoinhibition to excitation as it also did for DOI. Quipazine also caused renal sympathoexcitation in the presence (i.v.) of a vasopressin V1 receptor antagonist. 3. Injection (i.v.) of the V1 receptor antagonist at the peak pressor response evoked by quipazine alone and in the presence of SB204741 caused an immediate fall in MAP. For quipazine alone the renal sympathoinhibition was slowly reversed to an excitation, while the renal sympathoexcitation observed in the presence of SB204741 was potentiated. In both, the quipazine-evoked tachycardia was unaffected. 4. The data indicate that cardiovascular responses caused by i.c.v. quipazine and DOI are primarily due to activation of central 5-HT2A receptors, which causes the release of vasopressin and a tachycardia. This released vasopressin appears to suppress a 5-HT2A receptor-evoked central increase in sympathetic outflow, which involves the activation of central 5-HT2B receptors indirectly by the released vasopressin. (+info)Serotonin and NO complementarily regulate generation of oscillatory activity in the olfactory CNS of a terrestrial mollusk. (2/28)
Synchronous oscillation of membrane potentials, generated by assemblies of neurons, is a prominent feature in the olfactory systems of many vertebrate and invertebrate species. However, its generation mechanism is still controversial. Biogenic amines play important roles for mammalian olfactory learning and are also implicated in molluscan olfactory learning. Here, we investigated the role of serotonin, a biogenic amine, in the oscillatory dynamics in the procerebrum (PC), the molluscan olfactory center. Serotonin receptor blockers inhibited the spontaneous synchronous oscillatory activity of low frequency (approximately 0.5 Hz) in the PC. This was due to diminishing the periodic slow oscillation of membrane potential in bursting (B) neurons, which are essential neuronal elements for the synchronous oscillation in the PC. On the other hand, serotonin enhanced the amplitude of the slow oscillation in B neurons and subsequently increased the number of spikes in each oscillatory cycle. These results show that the extracellular serotonin level regulates the oscillation amplitude in B neurons and thus serotonin may be called an oscillation generator in the PC. Although nitric oxide (NO) is known to also be a crucial factor for generating the PC oscillatory activity and setting the PC oscillation frequency, the present study showed that NO only regulates the oscillation frequency in B neurons but could not increase the spikes in each oscillatory cycle. These results suggest complementary regulation of the PC oscillatory activity: NO determines the probability of occurrence of slow potentials in B neurons, whereas serotonin regulates the amplitude in each cycle of the oscillatory activity in B neurons. (+info)Quantification of serotonin transporters in nonhuman primates using [(123)I]ADAM and SPECT. (3/28)
We reported recently a highly selective radioligand, 2-([2-([dimethylamino]methyl)phenyl]thio)-5-[(123)I]iodophenylamine (ADAM), for SPECT imaging of serotonin transporters (SERT). In this article we describe the kinetic modeling of [(123)I]ADAM and its ability to quantitatively and reproducibly measure the concentrations of SERT in the nonhuman primate brain. We also investigate simplified models of tracer behavior that do not require invasive arterial blood sampling. METHODS: Three female baboons each underwent 3 [(123)I]ADAM SPECT studies. The studies consisted of a dynamic sequence of seventy-two 5-min scans after injection of 330 +/- 50 MBq (mean +/- SD) [(123)I]ADAM. Rapid arterial blood samples were obtained and corrected for the presence of labeled metabolites. Dynamic imaging and metabolite-corrected plasma data were analyzed using graphic analysis to give the distribution volumes (DVs) of different brain regions. DV ratios (DVRs) of target to cerebellum were derived and compared against a kinetic reference tissue model and simple target-to-background ratio. RESULTS: Averaged over all 9 scans, the mean DV in the midbrain was 4.86 +/- 1.06 mL/mL and the mean DV in the cerebellum was 2.25 +/- 0.48 mL/mL. The mean test-retest repeatability of the midbrain DV was 14.5%. The reference tissue model gave a mean midbrain DVR of 2.01 +/- 0.17 and correlated strongly with the DVR calculated from the full kinetic model (correlation coefficient [R(2)] = 0.94; P < 0.001), but with much improved repeatability (test-retest, 5.4%; intersubject variability, 5.2%). Similarly, the simple ratio method gave strong correlations with the full kinetic model (R(2) = 0.89; P < 0.001) and a test-retest of 7.6%. CONCLUSION: Accurate, repeatable quantification of SERT in the nonhuman primate brain is possible using kinetic modeling of dynamic [(123)I]ADAM SPECT scans. Simplified models, which do not require arterial blood sampling, gave accurate results that correlated strongly with the full kinetic model. The test-retest reliability of the simplified reference region models was excellent. Quantification of SERT is possible using full kinetic modeling and also with simpler reference region methods. (+info)Specific binding sites for 5-hydroxytryptamine on rat blood platelets. (4/28)
5-Hydroxytryptamine changes the shape of rat blood platelets by combination with a cinanserin-sensitive receptor which is not associated with the active uptake of 5-hydroxytryptamine. Binding of 5-hydroxy[3H]tryptamine to platelets at 4 degrees C demonstrates the presence of three saturable sites, and the highest-affinity site is apparently this 5-hydroxytryptamine receptor. (+info)Serotonergic control of cerebellar mossy fiber activity by modulation of signal transfer by rat pontine nuclei neurons. (5/28)
Serotonergic modulation of precerebellar nuclei may be crucial for the function of the entire cerebellar system. To study the effects of serotonin (5-HT) on neurons located within the pontine nuclei (PN), the main source of cerebellar mossy fibers, we performed standard intracellular recordings from PN neurons in a slice preparation of the rat pontine brain stem. Application of 5 microM 5-HT significantly altered several intrinsic membrane properties of PN neurons. First, it depolarized the somatic membrane potential by 6.5 +/- 3.5 mV and increased the apparent input resistance from 49.5 +/- 14.6 to 62.7 +/- 21.1 MOmega. Second, 5-HT altered the I-V relationship of PN neurons: it decreased the inward rectification in hyperpolarizing direction, but increased it when depolarizing currents were applied. Third, it decreased the rheobase from 0.32 +/- 0.14 to 0.24 +/- 0.14 nA without affecting the firing threshold. Finally, the amplitude of medium-duration after hyperpolarizations was reduced from -14.9 +/- 2.0 to -12.3 +/- 2.4 mV. Together, these 5-HT effects on the intrinsic membrane properties result in an increase in excitability and instantaneous firing rate. In addition, application of 5 microM 5-HT also modulated postsynaptic potentials (PSPs) evoked by electric stimulations within the cerebral peduncle. The amplitude, maximal slope, and integral of these PSPs were reduced to 46.2 +/- 23.4%, 45.7 +/- 23.7%, and 61.4 +/- 28.4% of the control value, respectively. In contrast, we found no change in the decay and voltage dependence of PSPs. To test modulatory effects on short-term synaptic facilitation, we applied pairs of electrical stimuli at intervals between 10 and 1,000 ms. 5-HT selectively enhanced the paired-pulse facilitation for interstimulus-intervals >20 ms. The alteration of paired-pulse facilitation points to a presynaptic site of action for 5-HT effects on synaptic transmission. Pharmacological experiments suggested that pre- and postsynaptic effects of 5-HT were mediated by two different kinds of 5-HT receptors: changes in intrinsic membrane properties were blocked by the 5-HT(2) receptor antagonist cinanserin while the reduction of PSPs was prevented by the 5-HT(1) receptor antagonist cyanopindolol. In conclusion, 5-HT increases the excitability of PN neurons but decreases the synaptic transmission on them. The selective enhancement of synaptic facilitation may, however, allow high-frequency inputs to effectively drive PN neurons, thus the PN may act as a high-pass filter during periods of 5-HT release. (+info)Characterization of the binding sites for 123I-ADAM and the relationship to the serotonin transporter in rat and mouse brains using quantitative autoradiography. (6/28)
Imaging of serotonin transporter (SERT) in the central nervous system may provide an important tool to evaluate some psychiatric disorders. Recently, a novel (123)I-labeled radiotracer, 2-((2-((dimethylamino)methyl)phenyl)thio)-5-iodophenylamine ((123)I-ADAM), has been developed that exhibited a high selectivity for SERT. The aim of this study was to characterize the biodistribution and specificity of (123)I-ADAM to SERT using quantitative autoradiography in both control and neurotoxin-treated animals. METHODS: (123)I-ADAM (74 MBq) was injected intravenously into the mice to access its biodistribution in the brain via quantitative autoradiography. Further, rats with serotonin depleted by intraperitoneal injection of p-chloroamphetamine (PCA) were used to evaluate the specificity of (123)I-ADAM to SERT. The levels of biogenic amines were then measured and correlated with quantitative (123)I-ADAM labeling in control and PCA-treated rat brains. RESULTS: The autoradiographic results showed that (123)I-ADAM accumulated in SERT-rich brain areas after systemic injection, including the globus pallidus, thalamus, hypothalamus, substantia nigra, interpeduncular nucleus, amygdala, and raphe nucleus. The dorsal raphe nucleus had the highest initial uptake with a peak specific binding ratio (i.e., [target - cerebellum]/cerebellum) at 120 min after injection. (123)I-ADAM uptake was dramatically decreased in the hippocampus, thalamus, amygdala, geniculate nuclei, hypothalamus, raphe nucleus, and substantia nigra in PCA-lesioned rats. The decrement in radioactivity was more prominent at higher dosages of PCA and was in parallel with the changes in amounts of serotonin and 5-hydroxyindoleacetic acid in the prefrontal cortex. CONCLUSION: This study demonstrates that regional distribution of (123)I-ADAM radioactivity is similar to the SERT localization in both rat and mouse brains. We also validated that destruction on central serotonergic neurons after PCA treatment inhibits the uptake of (123)I-ADAM in serotonin-rich brain regions. High specific binding to SERT in vivo makes (123)I-ADAM an appropriate radiotracer for solitary studies of serotonin functions in living humans. (+info)Biodistribution and imaging with (123)I-ADAM: a serotonin transporter imaging agent. (7/28)
2-((2-((Dimethylamino)methyl)phenyl)thio)-5-(123)I-iodophenylamine ((123)I-ADAM) is a new radiopharmaceutical that selectively binds the central nervous system serotonin transporters. The purpose of this study was to measure its whole-body biokinetics and estimate its radiation dosimetry in healthy human volunteers. The study was conducted within a regulatory framework that required its pharmacologic safety to be assessed simultaneously. METHODS: The sample included 7 subjects ranging in age from 22 to 54 y old. An average of 12.7 whole-body scans were acquired sequentially on a dual-head camera for up to 50 h after the intravenous administration of 185 MBq (5 mCi) (123)I-ADAM. The fraction of the administered dose in 13 regions of interest (ROIs) was quantified from the attenuation-corrected geometric mean counts in conjugate views. Multiexponential functions were iteratively fit to each time-activity curve using a nonlinear, least-squares regression algorithm. These curves were numerically integrated to yield source organ residence times. Gender-specific radiation doses were then estimated with the MIRD technique. SPECT brain scans obtained 3 h after injection were evaluated using an ROI analysis to determine the range of values for the region to cerebellum. RESULTS: There were no pharmacologic effects of the radiotracer on any of the subjects, including no change in heart rate, blood pressure, or laboratory results. Early planar images showed differentially increased activity in the lungs. SPECT images demonstrated that the radiopharmaceutical localized in the midbrain in a distribution that is consistent with selective transporter binding. The dose-limiting organ in both men and women was the distal colon, which received an average of 0.12 mGy/MBq (0.43 rad/mCi) (range, 0.098-0.15 mGy/MBq). The effective dose equivalent and effective dose for (123)I-ADAM were 0.037 +/- 0.003 mSv/MBq and 0.036 +/- 0.003 mSv/MBq, respectively. The mean adult male value of effective dose for (123)I-ADAM is similar in magnitude to that of (111)In-diethylenetriaminepentaacetic acid (0.035 mGy/MBq), half that of (111)In-pentetreotide (0.81 mGy/MBq), and approximately twice that of (123)I-inosine 5'-monophosphate (0.018 mGy/MBq). The differences in results between this study and a previous publication are most likely due to several factors, the most prominent being this dataset used attenuation correction of the scintigraphic data. Region-to-cerebellum ratios for the brain SPECT scans were 1.95 +/- 0.13 for the midbrain, 1.27 +/- 0.10 for the medial temporal regions, and 1.11 +/- 0.07 for the striatum. CONCLUSION: (123)I-ADAM may be a safe and effective radiotracer for imaging serotonin transporters in the brain and the body. (+info)Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro. (8/28)
The 3C-like proteinase (3CLpro) of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) is one of the most promising targets for anti-SARS-CoV drugs due to its crucial role in the viral life cycle. In this study, a database containing structural information of more than 8,000 existing drugs was virtually screened by a docking approach to identify potential binding molecules of SARS-CoV 3CLpro. As a target for screening, both a homology model and the crystallographic structure of the binding pocket of the enzyme were used. Cinanserin (SQ 10,643), a well-characterized serotonin antagonist that has undergone preliminary clinical testing in humans in the 1960s, showed a high score in the screening and was chosen for further experimental evaluation. Binding of both cinanserin and its hydrochloride to bacterially expressed 3CLpro of SARS-CoV and the related human coronavirus 229E (HCoV-229E) was demonstrated by surface plasmon resonance technology. The catalytic activity of both enzymes was inhibited with 50% inhibitory concentration (IC50) values of 5 microM, as tested with a fluorogenic substrate. The antiviral activity of cinanserin was further evaluated in tissue culture assays, namely, a replicon system based on HCoV-229E and quantitative test assays with infectious SARS-CoV and HCoV-229E. All assays revealed a strong inhibition of coronavirus replication at nontoxic drug concentrations. The level of virus RNA and infectious particles was reduced by up to 4 log units, with IC50 values ranging from 19 to 34 microM. These findings demonstrate that the old drug cinanserin is an inhibitor of SARS-CoV replication, acting most likely via inhibition of the 3CL proteinase. (+info)
123I-ADAM SPET imaging of serotonin transporter in patients with epilepsy and comorbid depression | BMC Neurology | Full Text
Discovery of novel GPVI receptor antagonists by structure-based repurposing. - Oxford Neuroscience
Brain serotonin transporter binding in non-depressed patients with Parkinsons disease - Guttman - 2007 - European Journal of...
NIOSHTIC-2 Publications Search - 20032138 - Aging, estradiol and time of day differentially affect serotonin transporter...
Brain, nutrition and metabolism
Wim Riedel - Research outputs - Maastricht University Research Portal
Buy 3-[[(Dimethylamino)carbonyl]oxy]-N,N,N-trimethylbenzenaminium methyl sulfate - 3-[[(Dimethylamino)carbonyl]oxy]-N,N,N...
67751-23-9, 4-(dimethylamino)-1,1-dimethoxybut-3-en-2-one, CAS No 67751-23-9 4-(dimethylamino)-1,1-dimethoxybut-3-en-2-one tr
PQR | 2-(dimethylamino)-1-(6-methyl-5,5-dioxidodibenzo[c,f][1,2,5]thiadiazepin-11(6h)-yl)ethanone
tryptamine - StarCraft II
Korky 2000BP, 2 Classic Toilet Flapper
Nucleus raphe obscurus
2-(4-chlorophenyl)-2-(dimethylamino)acetamide | C10H13ClN2O - ChemSynthesis
Liver Tissue Model Kit
3-bromophenyl)methyl][2-(dimethylamino)-4-methylpentyl]amine, made to order
9R)-9-[(dimethylamino)methyl]-6,7,10,11-tetrahydro-9H,18H-5,21:12,17-dimethenodibenzo[e,k]pyrrolo[3,4-h][1,4,13...
1-[3-(DIMETHYLAMINO)PROPYL]PIPERAZINE - Alfa Chemistry
SPECTRUM 2-[2-(Dimethylamino)Ethoxy]ethanol,500m - 29ZG96|D1756-500ML - Grainger
ITIS Standard Report Page: Chelidonichthys obscurus
Setiau Data Ymchwil - Porth Ymchwil - Ffurfwedd Safonol Converis
William Frans Christiaan Baaré
Geodermatophilus obscurus Luedemann ATCC ® 25078D-5™
Methanaminium,N-[bis(dimethylamino)methylene]-N-methyl-,chloride(1:1) - Alfa Chemistry
ChemIDplus - 22750-85-2 - KULWQNVVRBBMKK-VHEBQXMUSA-N - Quinoline, 5-((p-(dimethylamino)phenyl)azo)-, 1-oxide - Similar...
ChemIDplus - 22750-86-3 - CRIXZDJOKCDXJL-VHEBQXMUSA-N - Quinoline, 6-((p-(dimethylamino)phenyl)azo)-, 1-oxide - Similar...
PQR | 4-(dimethylamino)-3-methyl-1,2-diphenyl-1-butanol
Differences in serotonergic neurotransmission between rats displaying high or low anxiety/depression-like behaviour: effects of...
Failure of 5 methoxy tryptamine to evoke the bezold jarisch effect supports homology of excitatory 5 hydroxy tryptamine...
2-(dimethylamino)ethyl][(3-methylphenyl)methyl]amine | 2C91231 | 755008-06-1 | | MFCD09046178
My girl suffered from mitochondrial disease like Coronation Streets Oliver - I cant watch
Cirripectes obscurus - Viquipèdia, lenciclopèdia lliure
Extracellular matrix & 3D tissue models | Mimetas
Z)-3-(4-(2,2-bis(4-(dimethylamino)phenyl)-1-phenylvinyl)phenyl)-2-phenylacrylonitrile nanoparticles colloid
4-(dimethylamino)phenyl)(pyridin-3-yl)methanol (CAS No. 1409672-93-0) Suppliers @ ChemicalRegister.com
2-[[4-(dimethylamino)benzyl](methyl)amino]ethanol | C12H20N2O - ChemSynthesis
3-[(Dimethylamino)methyl]phenol | C9H13NO - PubChem
Cas 84255-31-2,N-[[5-(dimethylamino)-1-naphthyl]sulphonyl]-DL-leucine, compound with piperidine (1:1) | lookchem
Chemical Database: 1,2-Benzenediol, 4-(2-(dimethylamino)-1-hydroxyethyl)-, (R)-, phosphate (1:1) (salt) (EnvironmentalChemistry...
3-(2-(Dimethylamino)ethyl)indole sulfosalicylate | C19H22N2O6S - PubChem
Tetracaine CAS 94-24-6 - Zhuhai Jiayi Biotechnology Co, Ltd - ecplaza.net
ADAM12抗体|Abcam中国|Anti-ADAM12抗体(ab28747)
ADAM20抗体|Abcam中国|Anti-ADAM20抗体(ab118612)
Benzenemethanol,2-chloro-a-[2-(dimethylamino)ethyl]-a-phenyl-,hydrochloride (1:1) CAS 511-13-7 supplier price,buy Formaldehyde...
1-[2-(Dimethylamino)ethyl]piperazine 97% - OR6907 - 3644-18-6 from Apollo Scientific
difference b/w tryptose tryptophan and tryptamine? - Advanced Mycology - Shroomery Message Board
3-Bromo-n-[2-(dimethylamino)ethyl]benzamide | CAS No. 425618-78-6 | Sigma-Aldrich
Chemical Database: Pyridine, 2-((2-(dimethylamino)ethyl)-3-thenylamino)-, monohydrochloride (EnvironmentalChemistry.com)
CAS # 64-75-5, Tetracycline hydrochloride, [4S-(4alpha,4aalpha,5aalpha,6beta,12aalpha)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a...
4-(4-Dimethylaminoanilino)phenol
Serotonin Transporter | ChemScene llc
Serotonin Transporter | ChemScene llc
Dell spet Dellov @ Slo-Tech
5-HT2C receptor
Cinanserin Deramciclane Ketanserin LY-53,857 Metergoline Methiothepin Pizotifen Ritanserin S-32212 SB-206,553 SB-228,357 SB- ...
List of drugs: Ci
... cinanserin (INN) cinaproxen (INN) cinchocaine (INN) cinchophen (INN) cinecromen (INN) cinepaxadil (INN) cinepazet (INN) ...
C20H24N2OS
The molecular formula C20H24N2OS (molar mass: 340.48 g/mol, exact mass: 340.1609 u) may refer to: Cinanserin Lucanthone ...
Cinanserin
... (INN) is a 5-HT2A and 5-HT2C receptor antagonist which was discovered in the 1960s. The molecule is an inhibitor of ... June 2005). "Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly ...
Niaprazine
Cinanserin. *CSP-2503. *Deramciclane. *Dotarizine. *Eplivanserin. *Ergolines (e.g., amesergide, LY-53857, LY-215,840, ...
3,4-Methylenedioxy-N-ethylamphetamine
Cinanserin. *CSP-2503. *Deramciclane. *Dotarizine. *Eplivanserin. *Ergolines (e.g., amesergide, LY-53857, LY-215,840, ...
Lysergic acid 2,4-dimethylazetidide
Cinanserin. *CSP-2503. *Deramciclane. *Dotarizine. *Eplivanserin. *Ergolines (e.g., amesergide, LY-53857, LY-215,840, ...
2,5-Dimethoxy-4-propylamphetamine
Cinanserin. *CSP-2503. *Deramciclane. *Dotarizine. *Eplivanserin. *Ergolines (e.g., amesergide, LY-53857, LY-215,840, ...
WAY-100635
Cinanserin. *CSP-2503. *Deramciclane. *Dotarizine. *Eplivanserin. *Ergolines (e.g., amesergide, LY-53857, LY-215840, ...
5-Bromo-DMT
Cinanserin. *CSP-2503. *Deramciclane. *Dotarizine. *Eplivanserin. *Ergolines (e.g., amesergide, LY-53857, LY-215,840, ...
5-HT1 receptor
Cinanserin. *CSP-2503. *Deramciclane. *Dotarizine. *Eplivanserin. *Ergolines (e.g., amesergide, LY-53857, LY-215,840, ...
2C-T-2
Cinanserin. *CSP-2503. *Deramciclane. *Dotarizine. *Eplivanserin. *Ergolines (e.g., amesergide, LY-53857, LY-215840, ...
Cinanserin - Wikipedia
Cinanserin May Offer New Hope in Treating SARS
RxPG] Cinanserin, a drug that underwent preliminary clinical testing on humans in the 1960s, may inhibit the SARS virus say ... Cinanserin May Offer New Hope in Treating SARS. Jun 20, 2005 - 4:08:00 PM ... Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces ... Cinanserin, a well-characterized serotonin antagonist, scored high in the screening and was selected for further ...
Cinanserin - Alfa Chemistry
Drug Information Portal - Mobile - U.S. National Library of Medicine - Drug Search Results
Drug Information Portal - U.S. National Library of Medicine - Quick Access to Quality Drug Information
CIL:45974, Homo sapiens. CIL. Dataset
Effect of Hallucinogens on Unconditioned Behavior | SpringerLink
Erowid.org: Erowid Reference 3465 : Stimulus Properties of Phenethylamine Hallucinogens and Lysergic Acid Diethylamide: The...
Invertebrate serotonin receptors: a molecular perspective on classification and pharmacology | Journal of Experimental Biology
Plus it
Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines | SpringerLink
С ?? ҩ ??.??Ϣ?? .11202501??11203000
N-[(2S,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5...
5-HT2C receptor - Wikipedia
David Prince | Stanford Medicine Profiles
Coronavirus articles - free to access collection Home
Frontiers | Neural mechanisms underlying the generation of the lobster gastric mill motor pattern | Frontiers in Neural Circuits
Taraxacum officinale and Urtica dioica extracts inhibit dengue virus serotype 2 replication in vitro | BMC Complementary and...
5-HT Receptor Inhibitors | MedChemExpress
Plus it
ʸ ???? ӥ - ?? 륪 ??
Iodohippurate in English with contextual examples
Application # 2017/0189654. SYSTEM AND METHODS FOR TREATING MVO - Patents.com
FAC - 5-fluorouracil-adriamycin-cyclophosphamide | AcronymAttic
Niaprazine - Wikipedia
oxatomide - meddic
Cyproheptadine 4 mg tablet ivx / Revista pronto españa 2015
Serotonin antagonist1
- Cinanserin, a well-characterized serotonin antagonist, scored high in the screening and was selected for further experimentation. (rxpgnews.com)
Inhibitor2
- These findings demonstrate that the old drug cinanserin is an inhibitor of SARS-CoV replication, acting most likely via inhibition of the 3CL proteinase," say the researchers. (rxpgnews.com)
- Using the optimization guidelines, the SARS-CoV-2 Mpro inhibitor cinanserin was optimized resulting in an increase in binding affinity of 4.59 -log10(Kd) and increased protease inhibitor bioactivity. (bvsalud.org)
Humans1
- RxPG] Cinanserin, a drug that underwent preliminary clinical testing on humans in the 1960's, may inhibit the SARS virus say researchers from Europe and China. (rxpgnews.com)
Receptor1
- Cinanserin (INN) is a 5-HT2A and 5-HT2C receptor antagonist which was discovered in the 1960s. (wikipedia.org)
Simulation1
- The results of molecular dynamic (MD) simulation of cinanserin-optimized compounds CM02, CM06, and CM07 revealed that CM02 and CM06 fit well into the active site of SARS-CoV-2 Mpro [Protein Data Bank (PDB) accession number 6LU7] and formed strong and stable interactions with the key residues, Ser-144, His-163, and Glu-166. (bvsalud.org)